Mifepristone is an antiprogestin, meaning it competitively blocks progesterone receptors, and the question asks which clinical condition genuinely benefits from removing progesterone support.
The most familiar role is in medical abortion combined with a prostaglandin, but among the four choices given the appropriate match is uterine fibroid. Leiomyomas are progesterone-responsive tumours, so an antiprogestin can reduce their size and control associated heavy menstrual bleeding, an established medical use of the drug.
The remaining options do not fit. Threatened abortion calls for maintaining the pregnancy, often with progesterone supplementation, so a progesterone blocker would be exactly the wrong choice and is potentially harmful. Molar pregnancy is managed by surgical evacuation of the abnormal tissue rather than by any antiprogestin. Ectopic pregnancy has a well-defined medical treatment, methotrexate, which halts trophoblast growth; mifepristone is not the standard agent there. By straightforward elimination and by its known therapeutic profile, the correct condition is fibroid.
\[\boxed{\text{Fibroid}}\]